ADIA Research Grant Focused On Periodontal Disease
13th Apr 17
The Australian Dental Industry Association (ADIA) has provided funding into pioneering research that seeks to develop an innovative treatment option for periodontal disease. ADIA awarded the grant via the Australian Dental Research Foundation (ADRF), the nation's peak dental research funding body.
Key Issues For The Dental Industry —
The most recent ADIA Research Grant has been provided to Dr Asha Mathew who is a Postdoctoral Research Fellow at the Queensland University of Technology (QUT). The grant is supporting research into azithromycin surface-functionalized biodegradable membranes for guided tissue regeneration.
The objective of this research is to develop a calcium phosphate coated polycaprolactone electrospun membrane loaded with azithromycin for local and controlled antibiotic delivery. This will address the clinical challenge of membrane infection during guided bone regeneration and circumventing the limitations associated with the systemic administration of azithromycin.
There are two broad aims of the project. The first is to design and reproducibly manufacture polymeric fibrous membranes loaded with azithromycin and assess its performance in-vitro. The second is to assess the immune-modulatory effects of azithromycin loaded fibrous membrane in-vivo, in a critical size rodent calvarial defect model and also to assess its bone regeneration potential.
The importance of this research is underpinned by the fact that it is estimated that 30 to 40% of the total population is affected by periodontitis.
ADIA’s support for research in the dental and oral healthcare area is attributed to a long-standing support for the work of the ADRF, a body co-founded by ADIA.
ADIA's support for research into areas such as this is underpinned by the understanding that it often translates into new and innovative patient treatment and diagnostic treatment options.
Beyond funding research into potential products, ADIA also supports research into initiatives that will encourage Australians to take greater responsibility for their oral health.
The 2016-20 ADIA Strategic Plan signals the Association’s ongoing commitment to supporting research. ADIA’s vision is for an industry that empowers oral health professionals to advance the health and well-being of all Australians. This is something that is only possible as a result of the vital research funded through the ADRF and the funding provided by ADIA and others in the dental community.
Further Information —
For further information for ADIA's activities to support research into dental and oral healthcare issues please contact the ADIA National Office via email at firstname.lastname@example.org or telephone 1300 943 094. To keep up to date follow ADIA on Facebook at www.facebook.com/dental.industry or subscribe to the Twitter feed @AusDental.
Currency Of Information & Disclaimer —
This update was issued on 13 April 2017 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This publication is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, images and where stated.
9th Oct 17
The TGA is proposing that dental product manufacturers provide an information card when supplying a implantable medical device as an outcome of alignment of Australia's medical device regulations with that of the European Union.
26th Sep 17
The Australian Dental Industry Red Tape Index the fourth quarter of FY2016-17 jumped significantly to 58.7, indicating a moderate increase in regulatory compliance costs for the businesses that manufacture and supply dental products.